SCHEMBL6038316

SCHEMBL6038316

COCOc1cccc(COc2nccnc2NS(=O)(=O)c2ccc(C)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.46
AR P10275 1/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
CCR4 P51679 1/20 0.43
PPIF P30405 1/20 0.43
ALDH1A1 P00352 4/20 0.42
MAPT P10636 2/20 0.42
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
POLB P06746 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
CXCR2 P25025 1/20 0.39
AGTR1 P30556 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038504 0.91 MEN1 (0.50) F2ARKMT2AMEN1CCR4
SCHEMBL6038428 0.90 F2 (0.48) F2ARKMT2AMEN1CCR4
SCHEMBL6038899 0.90 F2 (0.47) F2ARKMT2AMEN1CCR4
SCHEMBL6038407 0.87 F2 (0.45) F2ARKMT2AMEN1CCR4
SCHEMBL6038839 0.87 F2 (0.49) F2ARKMT2AMEN1CCR4
SCHEMBL6039298 0.87 AR (0.51) F2ARKMT2AMEN1PPIF
SCHEMBL6038725 0.86 KMT2A (0.48) F2ARKMT2AMEN1CCR4
SCHEMBL6038680 0.86 F2 (0.46) F2ARKMT2AMEN1CCR4
SCHEMBL6038609 0.85 CCR4 (0.50) F2ARCCR4PPIFALDH1A1
SCHEMBL6038703 0.83 KMT2A (0.54) F2ARKMT2AMEN1CCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 F2 2305/4885AR 422/4885KMT2A 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.